Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Morphine-6-glucuronide: actions and mechanisms.

Gavin J Kilpatrick1, Terry W Smith

  • 1CeNeS Limited, Compass House, Vision Park, Histon, Cambridge CB4 9ZR, United Kingdom. gavin.kilpatrick@cenes.com

Medicinal Research Reviews
|June 14, 2005
PubMed
Summary

Morphine-6-glucuronide (M6G) offers pain relief similar to morphine but with fewer side effects like nausea and respiratory depression. Differences in receptor affinity, efficacy, and ADME profiles may explain these clinical variations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent.

Frontiers in pharmacology·2021
Same author

Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures.

Frontiers in immunology·2021
Same author

Impact of CPAP on activity patterns and diet in patients with obstructive sleep apnea (OSA).

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine·2014
Same author

You still need more than CPAP for OSA patients to lose weight.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine·2014
Same author

Impact of treatment with continuous positive airway pressure (CPAP) on weight in obstructive sleep apnea.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine·2013
Same author

Non-analgesic effects of opioids: opioid-induced respiratory depression.

Current pharmaceutical design·2012

Area of Science:

  • Pharmacology
  • Neuroscience
  • Clinical Medicine

Background:

  • Morphine-6-glucuronide (M6G) is a metabolite of morphine.
  • M6G is proposed to have comparable analgesic effects to morphine.
  • M6G may possess a more favorable side-effect profile, including reduced nausea, vomiting, and respiratory depression.

Purpose of the Study:

  • To review existing evidence comparing M6G and morphine.
  • To investigate the potential reasons for M6G's distinct clinical profile.
  • To identify knowledge gaps requiring further research.

Main Methods:

  • Literature review of pharmacological and clinical studies.
  • Analysis of data on micro-opioid and kappa-opioid receptor interactions.
  • Examination of absorption, distribution, metabolism, and excretion (ADME) profiles.

Related Experiment Videos

Main Results:

  • Both M6G and morphine activate the micro-opioid receptor.
  • Morphine exhibits slightly higher micro-opioid receptor affinity; M6G shows slightly higher efficacy.
  • M6G has lower kappa-opioid receptor affinity and a distinct ADME profile compared to morphine.

Conclusions:

  • Observed clinical differences between M6G and morphine are not fully explained by current data.
  • ADME differences are a likely contributor but may not be the sole factor.
  • Further research is needed to explore differential brain penetration and receptor characteristics in specific brain regions.